Adenocarcinoma of Lung
Welcome,         Profile    Billing    Logout  
 38 Companies   49 Products   49 Products   45 Mechanisms of Action   0 Trials   260 News 


123456»
  • ||||||||||  Enrollment change, Trial withdrawal:  Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Jan 24, 2019   
    P=N/A,  N=0, Withdrawn, 
    The first chemotherapy become a standard for patients with NSCL with asymptomatic brain metastases. N=261 --> 0 | Active, not recruiting --> Withdrawn
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. (clinicaltrials.gov) -  Dec 20, 2018   
    P2,  N=25, Terminated, 
    N=84 --> 0 | Terminated --> Withdrawn N=60 --> 25 | Trial completion date: Nov 2019 --> Jan 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Jan 2017; Low enrollment
  • ||||||||||  Gilotrif (afatinib) / Boehringer Ingelheim
    Trial primary completion date:  LUX-Lung 6: BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  Dec 14, 2018   
    P3,  N=364, Completed, 
    N=60 --> 25 | Trial completion date: Nov 2019 --> Jan 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Jan 2017; Low enrollment Trial primary completion date: Dec 2013 --> Nov 2017
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial completion:  Sunitinib in Never-Smokers With Lung Adenocarcinoma (clinicaltrials.gov) -  Sep 4, 2018   
    P2,  N=13, Completed, 
    Trial primary completion date: Dec 2013 --> Nov 2017 Active, not recruiting --> Completed
  • ||||||||||  topotecan / Generic mfg., vinorelbine tartrate / Generic mfg.
    Enrollment change, Combination therapy:  Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer (clinicaltrials.gov) -  Jun 2, 2018   
    P1,  N=18, Completed, 
    Active, not recruiting --> Completed | Trial completion date: May 2020 --> May 2018 N=36 --> 18
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Trial completion date, Trial primary completion date, Monotherapy, Metastases:  A Study Examining Maintenance Bevacizumab (Avastin (clinicaltrials.gov) -  Feb 23, 2018   
    P=N/A,  N=201, Completed, 
    N=36 --> 18 Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Jan 2018 | Trial primary completion date: Feb 2018 --> Jan 2018
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date, Monotherapy, Metastases:  A Study Examining Maintenance Bevacizumab (Avastin (clinicaltrials.gov) -  Dec 5, 2017   
    P=N/A,  N=200, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Feb 2018
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment closed, Monotherapy, Metastases:  A Study Examining Maintenance Bevacizumab (Avastin (clinicaltrials.gov) -  Oct 3, 2017   
    P=N/A,  N=200, Active, not recruiting, 
    Trial primary completion date: Oct 2017 --> Feb 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion, Trial primary completion date:  Study of Tumor Samples From Patients With Lung Cancer (clinicaltrials.gov) -  Aug 8, 2017   
    P=N/A,  N=280, Completed, 
    N=792 --> 313 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Nov 2013; DSMB recommendation Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Feb 2012
  • ||||||||||  Enrollment change, Trial initiation date, Trial termination, Metastases:  Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer (clinicaltrials.gov) -  Jul 28, 2017   
    P2,  N=17, Terminated, 
    Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Feb 2012 N=40 --> 17 | Initiation date: Aug 1998 --> Mar 1996 | Active, not recruiting --> Terminated; Slow accrual
  • ||||||||||  Biomarker, Trial completion:  Biomarkers for Diagnosis of Lung Cancer (clinicaltrials.gov) -  May 12, 2017   
    P=N/A,  N=300, Completed, 
    Not yet recruiting --> Completed | Trial primary completion date: Apr 2009 --> Apr 2008 Recruiting --> Completed
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Enrollment closed, Enrollment change:  Sunitinib in Never-Smokers With Lung Adenocarcinoma (clinicaltrials.gov) -  Jan 23, 2017   
    P2,  N=13, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=35 --> 13
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment closed, Trial primary completion date, Metastases:  Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. (clinicaltrials.gov) -  Oct 13, 2016   
    P2,  N=60, Active, not recruiting, 
    No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Nov 2015
  • ||||||||||  metformin / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date, Metastases:  Metformin in Stage IV Lung Adenocarcinoma (clinicaltrials.gov) -  Sep 30, 2016   
    P2,  N=13, Terminated, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Nov 2015 N=48 --> 13 | Recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Jun 2016; Difficult enrollment
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial primary completion date:  Sunitinib in Never-Smokers With Lung Adenocarcinoma (clinicaltrials.gov) -  Aug 11, 2016   
    P2,  N=35, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Aug 2017